PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16476030-5 2006 RESULTS: Following the dexamethasone treatment, the levels of TNF-alpha, IL-1-alpha, IL-6, and IL-8 were decreased significantly, and IL-1-alpha and IL-8 were detected at a level without a statistically significant difference from controls. Dexamethasone 23-36 interleukin 1 alpha Homo sapiens 73-83 16476030-5 2006 RESULTS: Following the dexamethasone treatment, the levels of TNF-alpha, IL-1-alpha, IL-6, and IL-8 were decreased significantly, and IL-1-alpha and IL-8 were detected at a level without a statistically significant difference from controls. Dexamethasone 23-36 interleukin 1 alpha Homo sapiens 134-144 15735656-3 2005 We have contrasted the effects of a synthetic glucocorticoid, dexamethasone, on thrombin- and IL-1alpha-stimulated GM-CSF production in human ASM cells. Dexamethasone 62-75 interleukin 1 alpha Homo sapiens 94-103 15735656-4 2005 Although IL-1alpha stimulated three-fold higher levels of GM-CSF mRNA and protein compared to thrombin, dexamethasone concentration-dependently reduced IL-1alpha-stimulated GM-CSF more potently and to a greater extent than the response to thrombin. Dexamethasone 104-117 interleukin 1 alpha Homo sapiens 152-161 15735656-7 2005 Dexamethasone treatment reduced luciferase expression stimulated by both IL-1alpha and thrombin. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 73-82 15735656-9 2005 This IL-1alpha-induced GM-CSF mRNA stability was prevented by either dexamethasone or the p38(MAPK) inhibitor, SB203580, neither of which influenced GM-CSF mRNA stability in thrombin-treated cells. Dexamethasone 69-82 interleukin 1 alpha Homo sapiens 5-14 15735656-10 2005 Dexamethasone inhibited p38(MAPK) phosphorylation in IL-1alpha-stimulated ASM, whereas thrombin does not stimulate p38(MAPK) phosphorylation. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 53-62 12951330-1 2003 Dexamethasone (DXM) interferes with the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) and can thereby diminish the secondary inflammatory response that follows initiation of antibacterial therapy. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 99-118 14633512-6 2004 In lung cells transfected with a fusion gene containing three TBEs fused to the basal SP-A promoter, Dex prevented the stimulatory effect of IL-1 on TTF-1 induction of SP-A promoter activity, suggesting that the GR inhibits SP-A promoter activity through the TBE. Dexamethasone 101-104 interleukin 1 alpha Homo sapiens 141-145 12951330-1 2003 Dexamethasone (DXM) interferes with the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) and can thereby diminish the secondary inflammatory response that follows initiation of antibacterial therapy. Dexamethasone 15-18 interleukin 1 alpha Homo sapiens 99-118 12391149-7 2002 The proinflammatory cytokine interleukin 1 (IL-1) induced MKP-1 expression in a p38-dependent manner and acted synergistically with dexamethasone to induce MKP-1 expression. Dexamethasone 132-145 interleukin 1 alpha Homo sapiens 29-48 11137138-7 2001 The addition of dexamethasone (required to reduce pain with the highest doses) inhibited IL-1alpha and enhanced the induction of IL-1ra by VRCTC-310-Onco. Dexamethasone 16-29 interleukin 1 alpha Homo sapiens 89-98 11250126-5 2001 In addition, DEX reduced the IL-1beta induced COX-2 immunoreactivity in the same concentration as wherein it inhibited PGE2 secretion. Dexamethasone 13-16 interleukin 1 alpha Homo sapiens 29-37 10476899-11 1999 Treatment of IL-1alpha-stimulated PDL cells with dexamethasone, known to inhibit COX-2 expression, prevented PGE2 production and COX-2 mRNA expression. Dexamethasone 49-62 interleukin 1 alpha Homo sapiens 13-22 10934644-7 2000 Osteoclast formation also was stimulated (in the presence of Dex) by prostaglandin E2 (PGE2), interleukin-11 (IL-11), IL-1, tumor necrosis factor-alpha (TNF-alpha), and parathyroid hormone-related protein (PTHrP), factors which also stimulate osteoclast formation supported by osteoblasts. Dexamethasone 61-64 interleukin 1 alpha Homo sapiens 118-151 10467228-7 1999 Dexamethasone markedly suppressed basal production of interleukin (IL)-6 and IL-11 and that stimulated by parathyroid hormone (PTH), IL-1alpha, or tumour necrosis factor-alpha in a dose-dependent manner. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 133-142 11169201-7 2001 IL-1, known to upregulate extrahepatic A-SAA gene expression in other cell systems only slightly, if at all, upregulated Dex-induced A-SAA expression by HASMC. Dexamethasone 121-124 interleukin 1 alpha Homo sapiens 0-4 10690884-0 2000 Interleukin-1 receptor antagonist ribonucleic acid and protein expression by cultured Graves" and normal orbital fibroblasts is differentially modulated by dexamethasone and irradiation. Dexamethasone 156-169 interleukin 1 alpha Homo sapiens 0-13 10443472-0 1999 Dexamethasone inhibits collagen degradation induced by the combination of interleukin-1 and plasminogen in cartilage explant culture. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 74-87 10443472-4 1999 Dexamethasone clearly blocked collagen degradation induced by the combination of interleukin-1 (IL-1) and plasminogen at the concentration of 10(-9) M, which is much lower than the concentrations reportedly required to inhibit matrix synthesis. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 81-94 10443472-4 1999 Dexamethasone clearly blocked collagen degradation induced by the combination of interleukin-1 (IL-1) and plasminogen at the concentration of 10(-9) M, which is much lower than the concentrations reportedly required to inhibit matrix synthesis. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 96-100 10102285-0 1999 Differential inhibition of collagenase and interleukin-1alpha gene expression in cultured corneal fibroblasts by TGF-beta, dexamethasone, and retinoic acid. Dexamethasone 123-136 interleukin 1 alpha Homo sapiens 43-61 10429944-11 1999 Dexamethasone, over a wide range of concentrations, markedly enhanced proteoglycan synthesis and completely reversed the downregulatory effects of IL-1 and IL-6 + sIL-6Ralpha. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 147-151 10334936-9 1999 IL-1 alone slightly decreases the basal production of angiogenin protein and mRNA, but essentially abolishes the response to IL-6 in the absence or presence of dexamethasone. Dexamethasone 160-173 interleukin 1 alpha Homo sapiens 0-4 11096704-5 1999 Dexa- methasone inhibits synthesis of the inflammatory cytokines, interleukin-1 and tumor necrosis factor. Dexamethasone 0-15 interleukin 1 alpha Homo sapiens 66-105 10217524-0 1999 Interleukin-1alpha and tumour necrosis factor-alpha modulate airway smooth muscle DNA synthesis by induction of cyclo-oxygenase-2: inhibition by dexamethasone and fluticasone propionate. Dexamethasone 145-158 interleukin 1 alpha Homo sapiens 0-18 10217524-7 1999 The cytokine mixture, comprising IL-1alpha (0.01 and 0.1 pM) and TNF-alpha (3 and 30 pM), directly evoked increases in DNA synthesis which were attenuated by dexamethasone. Dexamethasone 158-171 interleukin 1 alpha Homo sapiens 33-42 9648943-4 1998 Northern analyses showed that IL-1-dependent collagenase mRNA production was significantly decreased in the presence of dexamethasone. Dexamethasone 120-133 interleukin 1 alpha Homo sapiens 30-34 9767285-9 1998 The production of IL-1 alpha/IL-6 was inhibited up to 80/89% (10-7-10-6 mol/L before and after irradiation) by dexamethasone in a concentration-dependent manner and with all conditions of incubation. Dexamethasone 111-124 interleukin 1 alpha Homo sapiens 18-28 9648943-8 1998 CAT transfection studies utilizing collagenase promoter demonstrated a dose-dependent transcriptional inhibition of IL-1-induced gingival collagenase gene expression by dexamethasone. Dexamethasone 169-182 interleukin 1 alpha Homo sapiens 116-120 8728019-3 1996 The synthetic glucocorticoid dexamethasone 1) inhibits the LPS-initiated vascular leak of plasma proteins into the airspace, 2) inhibits the LPS-initiated emigration of neutrophils and lymphocytes into the airspace in a dose-dependent fashion, and 3) inhibits LPS-initiated mRNA and/or bronchoalveolar lavage protein expression of cytokines (TNF, IL-1 and IL-6) and chemokines (MIP-1 alpha, MIP-2 and MCP-1). Dexamethasone 29-42 interleukin 1 alpha Homo sapiens 347-351 9496264-5 1997 Dexamethasone decreased the IL-1-stimulated IL-6 release in all cases. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 28-32 9389931-3 1997 Dexamethasone and noradrenaline suppressed secretion of IL-2, IFN alpha, IFN gamma, TNF alpha, IL-1 alpha and IL-1 beta. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 95-105 8796788-6 1996 IL-1-induced PG production was also suppressed by dexamethasone, by the natural IL-1 receptor antagonist (IL-1ra), and by transforming growth factor1 beta (TGF1 beta). Dexamethasone 50-63 interleukin 1 alpha Homo sapiens 0-4 9367827-4 1997 The synergistic interaction between PMA and Dex on G-CSF production appeared to be mediated through the production of interleukin-1 (IL-1) since neutralization of IL-1 activity completely inhibited G-CSF production. Dexamethasone 44-47 interleukin 1 alpha Homo sapiens 118-131 9367827-4 1997 The synergistic interaction between PMA and Dex on G-CSF production appeared to be mediated through the production of interleukin-1 (IL-1) since neutralization of IL-1 activity completely inhibited G-CSF production. Dexamethasone 44-47 interleukin 1 alpha Homo sapiens 133-137 9367827-4 1997 The synergistic interaction between PMA and Dex on G-CSF production appeared to be mediated through the production of interleukin-1 (IL-1) since neutralization of IL-1 activity completely inhibited G-CSF production. Dexamethasone 44-47 interleukin 1 alpha Homo sapiens 163-167 9368513-8 1997 In Graves" and multinodular goitre thyrocytes, inhibition of IL-1 (100 U/ml)-stimulated IL-6 release by dexamethasone (100 nmol/l) was 62.51% +/- 10.43 (S.E.M. Dexamethasone 104-117 interleukin 1 alpha Homo sapiens 61-65 8867766-7 1996 Dexamethasone (10(-7) M), known to inhibit inflammatory reactions and retard wound healing, also inhibited the induction of KGF mRNA expression by IL-1 alpha, IL-1 beta and TNF-alpha. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 147-157 8536785-7 1996 IL-1 alpha-induced GM-CSF, IL-1 beta, IL-6, IL-11, and LIF mRNA levels were reduced by the addition of dexamethasone, whereas dexamethasone had no influence on the amounts of IL-1 alpha-induced G-CSF mRNA. Dexamethasone 103-116 interleukin 1 alpha Homo sapiens 0-10 8536785-7 1996 IL-1 alpha-induced GM-CSF, IL-1 beta, IL-6, IL-11, and LIF mRNA levels were reduced by the addition of dexamethasone, whereas dexamethasone had no influence on the amounts of IL-1 alpha-induced G-CSF mRNA. Dexamethasone 126-139 interleukin 1 alpha Homo sapiens 0-10 7621583-4 1995 When dexamethasone or hydrocortisone were added to IL-1 alpha, significant potentialization of IL-1 alpha-induced stimulation of C3 and factor B production was observed, occurring at various concentrations of either stimuli. Dexamethasone 5-18 interleukin 1 alpha Homo sapiens 51-61 7579343-9 1995 In striking contrast to what was observed for IL-1 alpha, the synthetic GC dexamethasone (DXM) at a concentration of 10(-6) mol/L consistently inhibited the basal secretion of LIF/HILDA by an average of threefold and suppressed the IL-1 alpha-induced increase of the secretion of this cytokine by HUVEC. Dexamethasone 75-88 interleukin 1 alpha Homo sapiens 232-242 7579343-9 1995 In striking contrast to what was observed for IL-1 alpha, the synthetic GC dexamethasone (DXM) at a concentration of 10(-6) mol/L consistently inhibited the basal secretion of LIF/HILDA by an average of threefold and suppressed the IL-1 alpha-induced increase of the secretion of this cytokine by HUVEC. Dexamethasone 90-93 interleukin 1 alpha Homo sapiens 232-242 7579343-12 1995 Again, IL-1 alpha proved to be a very potent stimulus for the secretion of LIF/HILDA and synthetic GC such as DXM when used at a concentration of 10(-6) mol/L inhibited by an average of threefold the basal secretion of LIF/HILDA and had suppressive effect on the IL-1 alpha-induced increase of this secretion. Dexamethasone 110-113 interleukin 1 alpha Homo sapiens 7-17 7579343-12 1995 Again, IL-1 alpha proved to be a very potent stimulus for the secretion of LIF/HILDA and synthetic GC such as DXM when used at a concentration of 10(-6) mol/L inhibited by an average of threefold the basal secretion of LIF/HILDA and had suppressive effect on the IL-1 alpha-induced increase of this secretion. Dexamethasone 110-113 interleukin 1 alpha Homo sapiens 263-273 7608556-4 1995 Dexamethasone completely inhibited IL-1-induced COX-2 mRNA expression. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 35-39 7621583-4 1995 When dexamethasone or hydrocortisone were added to IL-1 alpha, significant potentialization of IL-1 alpha-induced stimulation of C3 and factor B production was observed, occurring at various concentrations of either stimuli. Dexamethasone 5-18 interleukin 1 alpha Homo sapiens 95-105 7621583-6 1995 In contrast, dexamethasone counteracts, in an additive way, the inhibitory effect of IL-1 alpha on regulatory complement protein factor H production by EC. Dexamethasone 13-26 interleukin 1 alpha Homo sapiens 85-95 7775626-9 1995 To a lesser extent, the combination of interleukin-1, interleukin-6, and tumor necrosis factor-alpha also counteracted the effects of dexamethasone. Dexamethasone 134-147 interleukin 1 alpha Homo sapiens 39-52 7927949-4 1994 The antiproliferative effect of IL-1 alpha was additive to the inhibition of cell proliferation caused by dihydrotestosterone (DHT) or the glucocorticoid dexamethasone (DEX). Dexamethasone 154-167 interleukin 1 alpha Homo sapiens 32-42 7884317-6 1995 The anti-inflammatory agent, dexamethasone, was the most potent agent in controlling the SE-mediated effects as evidenced by inhibited T cell proliferation (55%) and reduced levels of IL-1, IL-6, and IFN gamma (60% to 100%) and TNF alpha (50%). Dexamethasone 29-42 interleukin 1 alpha Homo sapiens 184-188 7957239-3 1994 Northern-blot analysis revealed that both cPLA2 and cyclooxygenase-2 mRNA were progressively upregulated upon exposure to IL-1 for 5 hours and the glucocorticoid, dexamethasone, blocked the increased expression of these two genes. Dexamethasone 163-176 interleukin 1 alpha Homo sapiens 122-126 7957239-4 1994 In contrast, IL-1-induced sPLA2 gene expression determined in the same cell samples was weak and most often rapid, and dexamethasone further stimulated it. Dexamethasone 119-132 interleukin 1 alpha Homo sapiens 13-17 7927949-5 1994 In parallel, IL-1 alpha-induced stimulation of apo-D and GCDFP-15 secretion was additive to that exerted by DHT or DEX. Dexamethasone 115-118 interleukin 1 alpha Homo sapiens 13-23 7706493-4 1995 In F-nl, incubation with the agonists PMA, LPS, or IL-1 increased COX activity and protein expression of the inducible form of COX, COX-2, and these responses were inhibited by coincubation with dexamethasone. Dexamethasone 195-208 interleukin 1 alpha Homo sapiens 51-55 7927949-4 1994 The antiproliferative effect of IL-1 alpha was additive to the inhibition of cell proliferation caused by dihydrotestosterone (DHT) or the glucocorticoid dexamethasone (DEX). Dexamethasone 169-172 interleukin 1 alpha Homo sapiens 32-42 7519403-0 1994 Dexamethasone inhibits IL-1 and TNF activity in human lung fibroblasts without affecting IL-1 or TNF receptors. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 23-27 7947352-5 1994 Specifically, RU486 (at concentrations of 1-100 nM) exerts pure antagonist actions by almost completely reversing the inhibitory effects of the glucocorticoid dexamethasone (Dex) on the release of monocyte/macrophages-derived lymphokines, such as IL-1, IL-6, IL-8 and tumor necrosis factor-alpha (TNF-alpha). Dexamethasone 159-172 interleukin 1 alpha Homo sapiens 247-251 7947352-5 1994 Specifically, RU486 (at concentrations of 1-100 nM) exerts pure antagonist actions by almost completely reversing the inhibitory effects of the glucocorticoid dexamethasone (Dex) on the release of monocyte/macrophages-derived lymphokines, such as IL-1, IL-6, IL-8 and tumor necrosis factor-alpha (TNF-alpha). Dexamethasone 174-177 interleukin 1 alpha Homo sapiens 247-251 7947352-6 1994 Dex decreased in a dose-dependent manner the release of the above four lymphokines, with an ID50 of 0.9 +/- 0.1, 4.76 +/- 0.4, 9.8 +/- 1.8, and 1.16 +/- 0.2 nM for IL-1, IL-6, IL-8 and TNF-alpha, respectively. Dexamethasone 0-3 interleukin 1 alpha Homo sapiens 164-168 8034668-8 1994 Dexamethasone alone did not increase PAI-1 mRNA accumulation but enhanced it in combination with IL-1. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 97-101 7519403-7 1994 Both IL-1 and TNF increased release of IL-6 and IL-8 from the cells in a dose-dependent manner and dexamethasone inhibited this effect. Dexamethasone 99-112 interleukin 1 alpha Homo sapiens 5-9 7519403-8 1994 Dexamethasone also inhibited the induction of IL-6 and IL-8 RNA by IL-1 and TNF. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 67-79 7519403-3 1994 Dexamethasone blocks the induction of IL-6 and IL-8 by IL-1 or TNF. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 55-66 7519403-4 1994 In these studies, we determined whether dexamethasone interferes with the upregulation of IL-6 and IL-8 by downregulating expression of the IL-1 or TNF receptor genes. Dexamethasone 40-53 interleukin 1 alpha Homo sapiens 140-144 7516173-9 1994 However, the magnitude of this effect could not fully account for the potency of the glucocorticoid-induced alterations in IL-6 mRNA accumulation and protein production since 10(-6) M dexamethasone caused only a 50% decrease in IL-1-induced IL-6 gene transcription. Dexamethasone 184-197 interleukin 1 alpha Homo sapiens 228-232 8004813-6 1994 Dexamethasone suppressed both gene expression and protein production of GM-CSF, IL-6 and IL-8 when fibroblasts were exposed to IL-1 alpha. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 127-137 8175759-2 1994 A glucocorticoid, dexamethasone, inhibited the production of a leukocyte chemotactic cytokine, interleukin 8 (IL-8), as well as mRNA expression by a glioblastoma cell line, T98G, stimulated with interleukin 1 (IL-1). Dexamethasone 18-31 interleukin 1 alpha Homo sapiens 210-214 8175759-3 1994 Dexamethasone also inhibited IL-8 promoter-driven chloramphenicol acetyltransferase (CAT) activities induced by IL-1, suggesting that dexamethasone inhibited IL-8 production mainly at the transcriptional level. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 112-116 8175759-3 1994 Dexamethasone also inhibited IL-8 promoter-driven chloramphenicol acetyltransferase (CAT) activities induced by IL-1, suggesting that dexamethasone inhibited IL-8 production mainly at the transcriptional level. Dexamethasone 134-147 interleukin 1 alpha Homo sapiens 112-116 8175759-7 1994 Finally, dexamethasone diminished the IL-1-induced formation of NF-kappa B complexes, which were identified immunochemically to consist of p50 and p65, without reducing the amount of translocated factors. Dexamethasone 9-22 interleukin 1 alpha Homo sapiens 38-42 8159722-10 1994 In addition, cultured smooth muscle cells expressed SAA1, SAA2, and SAA4 mRNAs when treated with interleukin 1 or 6 (IL-1 or IL-6) in the presence of dexamethasone. Dexamethasone 150-163 interleukin 1 alpha Homo sapiens 97-115 8159722-10 1994 In addition, cultured smooth muscle cells expressed SAA1, SAA2, and SAA4 mRNAs when treated with interleukin 1 or 6 (IL-1 or IL-6) in the presence of dexamethasone. Dexamethasone 150-163 interleukin 1 alpha Homo sapiens 117-121 8294881-10 1994 The induction by Dex of the type II receptor, a decoy molecule for IL-1, may contribute to the immunosuppressive and antiinflammatory activities of Dex. Dexamethasone 17-20 interleukin 1 alpha Homo sapiens 67-71 8147926-6 1994 RESULTS: IL-1 induced an increase in COX activity (as assessed by prostaglandin E2 release) that was dose- and time-dependent and was blocked by cycloheximide, actinomycin D, and dexamethasone. Dexamethasone 179-192 interleukin 1 alpha Homo sapiens 9-13 8147926-7 1994 IL-1 induced a selective increase in COX II mRNA and biosynthesis of COX II protein that was blocked by dexamethasone. Dexamethasone 104-117 interleukin 1 alpha Homo sapiens 0-4 8294881-6 1994 Induction of IL-1R II mRNA by Dex was associated with augmented membrane expression and release of the type II IL-1 binding molecule. Dexamethasone 30-33 interleukin 1 alpha Homo sapiens 13-17 8294881-10 1994 The induction by Dex of the type II receptor, a decoy molecule for IL-1, may contribute to the immunosuppressive and antiinflammatory activities of Dex. Dexamethasone 148-151 interleukin 1 alpha Homo sapiens 67-71 8294881-9 1994 The concentrations of IL-1 alpha and IL-1 receptor antagonist required to displace the binding of IL-1 beta to the soluble form of the decoy molecule induced by Dex from PMN were, respectively, 100 and 2 times higher compared with IL-1 beta. Dexamethasone 161-164 interleukin 1 alpha Homo sapiens 22-32 8468485-0 1993 Cytokines and dexamethasone modulation of IL-1 receptors on human neutrophils in vitro. Dexamethasone 14-27 interleukin 1 alpha Homo sapiens 42-46 7507497-8 1994 The synthetic glucocorticoid hormone dexamethasone (DEX) blocks the LPS induction of SP with a Ki approximating 8 x 10(-11) M. The inhibition is due in part to the blockade of the LPS induction of ganglionic IL-1 mRNA. Dexamethasone 37-50 interleukin 1 alpha Homo sapiens 208-212 7507497-8 1994 The synthetic glucocorticoid hormone dexamethasone (DEX) blocks the LPS induction of SP with a Ki approximating 8 x 10(-11) M. The inhibition is due in part to the blockade of the LPS induction of ganglionic IL-1 mRNA. Dexamethasone 52-55 interleukin 1 alpha Homo sapiens 208-212 8225873-9 1993 When added together, dexamethasone antagonizes the interleukin-1 alpha-induced increase of stromelysin, gelatinase B, and TIMP1 in a dose-dependent manner. Dexamethasone 21-34 interleukin 1 alpha Homo sapiens 51-70 7691110-6 1993 The TNF alpha/IL-1-stimulated GM-CSF release was blocked by the addition of 1 microM dexamethasone, whereas basal CSF-1 release was unaffected. Dexamethasone 85-98 interleukin 1 alpha Homo sapiens 14-18 8388949-6 1993 In addition, the following values were decreased after dexamethasone therapy in the early treatment group: number of neutrophils in tracheobronchial aspirate fluid (p < 0.05), and concentrations of leukotriene B4 (p < 0.01), interleukin-1 (p < 0.01), elastase-alpha 1-proteinase inhibitor (p < 0.01), and albumin (p < 0.01). Dexamethasone 55-68 interleukin 1 alpha Homo sapiens 231-244 8288917-8 1994 Dexamethasone (10 nM), and the protein synthesis inhibitors actinomycin D (1 microM) and cycloheximide (3 micrograms/ml) completely abolished the effect of interleukin-1 on 15-HETE formation. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 156-169 8468485-6 1993 Further studies showed that dexamethasone and GM-CSF (or G-CSF) synergistically increased IL-1 binding after 8 h. This synergistic modulation was a cytokine dose- and time-dependent process, and was due to an increase in IL-1R numbers rather than a change in binding affinity. Dexamethasone 28-41 interleukin 1 alpha Homo sapiens 90-94 8468485-7 1993 In addition, human bone marrow neutrophils, cord blood neutrophils, and several human hematopoietic cell lines (HL-60, U-937, and AML-193) responded to dexamethasone and GM-CSF (or G-CSF) with a superadditive increase in IL-1 binding. Dexamethasone 152-165 interleukin 1 alpha Homo sapiens 221-225 8432990-4 1993 Evidence is presented for down-regulation of the IL-1-induced LIF activity by an endogenous cyclo-oxygenase product(s); the glucocorticoid, dexamethasone, lowered the IL-1-induced LIF activity and mRNA expression. Dexamethasone 140-153 interleukin 1 alpha Homo sapiens 49-53 8482109-8 1993 The IL-1 alpha-induced mRNA and protein production were inhibited by dexamethasone. Dexamethasone 69-82 interleukin 1 alpha Homo sapiens 4-14 8432990-4 1993 Evidence is presented for down-regulation of the IL-1-induced LIF activity by an endogenous cyclo-oxygenase product(s); the glucocorticoid, dexamethasone, lowered the IL-1-induced LIF activity and mRNA expression. Dexamethasone 140-153 interleukin 1 alpha Homo sapiens 167-171 1472130-7 1992 The glucocorticoid dexamethasone (10(-6) to 10(-7) M) inhibited IL-1-stimulated PAI-2 formation but reversed the suppressive effect of IL-1 on PAI-1 production. Dexamethasone 19-32 interleukin 1 alpha Homo sapiens 64-68 8429822-2 1993 Dexamethasone (DEX) decreased levels of IL-1 alpha and IL-1 beta mRNAs in a dose-related fashion. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 40-50 8429822-2 1993 Dexamethasone (DEX) decreased levels of IL-1 alpha and IL-1 beta mRNAs in a dose-related fashion. Dexamethasone 15-18 interleukin 1 alpha Homo sapiens 40-50 8429822-3 1993 The DEX-induced decrease in levels of IL-1 alpha and IL-1 beta mRNAs was abolished by the steroid receptor antagonist RU486. Dexamethasone 4-7 interleukin 1 alpha Homo sapiens 38-48 8429822-4 1993 The levels of IL-1 alpha and IL-1 beta proteins within the cells and of IL-1 beta in the culture medium were decreased by DEX to comparable extents, so that DEX had no detectable effect on cytokine secretion. Dexamethasone 122-125 interleukin 1 alpha Homo sapiens 14-24 1472130-7 1992 The glucocorticoid dexamethasone (10(-6) to 10(-7) M) inhibited IL-1-stimulated PAI-2 formation but reversed the suppressive effect of IL-1 on PAI-1 production. Dexamethasone 19-32 interleukin 1 alpha Homo sapiens 135-139 1384479-6 1992 The stimulatory effect of both IL-1 alpha and IL-1 beta and the synergistical stimulation with TPA were completely abrogated by 10 ng/ml TGF-beta 1 or 1 microM dexamethasone. Dexamethasone 160-173 interleukin 1 alpha Homo sapiens 31-41 1429687-4 1992 The glucocorticoid, dexamethasone, blocks the IL-1 alpha-mediated increases in both cPLA2 and PGE2 without affecting the cyclooxygenase level. Dexamethasone 20-33 interleukin 1 alpha Homo sapiens 46-56 1636747-11 1992 This occurs because DEX inhibits the IL-1-induced enhanced arachidonate release. Dexamethasone 20-23 interleukin 1 alpha Homo sapiens 37-41 1390947-3 1992 We have studied the effects of indomethacin, dexamethasone and aurothioglucose (which have been used in the treatment of patients affected by rheumatoid arthritis) in the IL-1 inducible CAT assay. Dexamethasone 45-58 interleukin 1 alpha Homo sapiens 171-175 1390947-4 1992 We show that aurothioglucose or dexamethasone is able to inhibit IL-1 induced CAT activity whereas a non-steroidal anti-inflammatory drug (indomethacin) is inactive. Dexamethasone 32-45 interleukin 1 alpha Homo sapiens 65-69 1636747-6 1992 IL-1-induced COX mass was maintained at an increased level for at least 48 h. The glucocorticoid dexamethasone (DEX) virtually abolished prostaglandin production and blocked cytokine induction of COX activity and mass. Dexamethasone 97-110 interleukin 1 alpha Homo sapiens 0-4 1636747-6 1992 IL-1-induced COX mass was maintained at an increased level for at least 48 h. The glucocorticoid dexamethasone (DEX) virtually abolished prostaglandin production and blocked cytokine induction of COX activity and mass. Dexamethasone 112-115 interleukin 1 alpha Homo sapiens 0-4 1550404-10 1992 In contrast, dexamethasone (10(-6) mol/l) suppressed the ability of IL-1 to increase the expression of IL-6 mRNA. Dexamethasone 13-26 interleukin 1 alpha Homo sapiens 68-72 1592440-2 1992 Over a wide dose range, dexamethasone inhibited IL-8 production induced by IL-1 alpha stimulation. Dexamethasone 24-37 interleukin 1 alpha Homo sapiens 75-85 19912845-0 1992 Increased sensitivity of glioblastoma cells to interleukin 1 after long-term incubation with dexamethasone. Dexamethasone 93-106 interleukin 1 alpha Homo sapiens 47-60 1532379-1 1992 Pretreatment of epidermal cells (EC) with hydrocortisone or dexamethasone abolishes their capacity to produce interleukin-1 (IL-1) and therefore reduces their capacity to support proliferative response of lectin-stimulated T cells. Dexamethasone 60-73 interleukin 1 alpha Homo sapiens 125-129 19912845-5 1992 However, when cells were preincubated in the presence of DEX for 15 h and then challenged with IL 1beta or IL 1beta and DEX, there was a left-shift in the IL 1,B dose-response curve, suggesting an increased sensitivity of the cells to respond to IL 1 and produce IL 6. Dexamethasone 57-60 interleukin 1 alpha Homo sapiens 95-99 19912845-7 1992 However, maximum IL 6 production at high doses of IL 1beta was inhibited in cells cultured in the presence of DEX during the IL 1 challenge. Dexamethasone 110-113 interleukin 1 alpha Homo sapiens 50-54 1752957-5 1991 However, eosinophil viability decreased by 21% in dexamethasone-pretreated IL-1 alpha-stimulated endothelial cell-conditioned medium (P less than 0.05), which suggested viability antagonism by glucocorticoids. Dexamethasone 50-63 interleukin 1 alpha Homo sapiens 75-85 2031055-8 1991 In addition, combining IL-1 with dexamethasone, a synthetic glucocorticoid that enhances some IL-1 actions, produced only additive, not synergistic, increases in Cu-Zn SOD activities. Dexamethasone 33-46 interleukin 1 alpha Homo sapiens 94-98 1651357-6 1991 Similar results were obtained for the effect of dexamethasone on the induction of SAA by IL-6 plus IL-1 alpha. Dexamethasone 48-61 interleukin 1 alpha Homo sapiens 99-109 1714833-11 1991 Dexamethasone (10(-6) M) suppressed both basal and IL-1- and TNF-induced IL-6 mRNA expression. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 51-77 1826853-6 1991 The fact that Dex treatment also reduced the level of circulating M-CSF after rhuIL-1 administration suggests that the inhibitory effects of IL-1 are mediated through locally produced M-CSF. Dexamethasone 14-17 interleukin 1 alpha Homo sapiens 81-85 2085666-1 1990 The effect of dexamethasone on the in vitro release of IL-1 and IL-3-LA by human unstimulated mononuclear cells was studied. Dexamethasone 14-27 interleukin 1 alpha Homo sapiens 55-59 1981242-4 1990 Dexamethasone (10-100 nM) inhibited IL-1 production and IL-1 mediated thymocyte proliferation. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 36-40 1981242-4 1990 Dexamethasone (10-100 nM) inhibited IL-1 production and IL-1 mediated thymocyte proliferation. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 56-60 2085666-0 1990 Effect of dexamethasone on IL-1 and IL-3-LA release by unstimulated human mononuclear cells. Dexamethasone 10-23 interleukin 1 alpha Homo sapiens 27-31 2007786-6 1991 Addition of hydrocortisone, prednisolone, or dexamethasone immediately after UVB irradiation significantly blocked UVB or IL-1-induced IL-6 mRNA expression and production by EC. Dexamethasone 45-58 interleukin 1 alpha Homo sapiens 122-126 1925068-7 1991 Absence of IL-1 activity was noted in supernatants of monocyte cultures in the presence of dexamethasone. Dexamethasone 91-104 interleukin 1 alpha Homo sapiens 11-15 2390678-13 1990 Intravenous administration of the steroidal anti-inflammatory agent dexamethasone (3 mg kg-1) 1 h before either cytokine attenuated the fever induced by IL-1 alpha (2500 u kg-1) and IL-1 beta (500 u kg-1). Dexamethasone 68-81 interleukin 1 alpha Homo sapiens 153-163 34265332-8 2021 The administered nanodevice (intravenously by tail vein injection) accumulated in the injured lungs and the controlled dexamethasone release reduces markedly the inflammatory response (TNF-alpha IL-6 and IL-1beta levels). Dexamethasone 119-132 interleukin 1 alpha Homo sapiens 204-212 33802355-5 2021 The top five drug compound candidates underwent in vitro validation in NF-kappaB-based luciferase reporter A549 cells stimulated by IL-1beta +- dexamethasone. Dexamethasone 144-157 interleukin 1 alpha Homo sapiens 132-140 35110698-4 2022 HT-15 can selectively act on the NF-kappaB/AP1-mediated transrepression function of glucocorticoid receptor (GR) and repress the expression of pro-inflammation cytokines (i.e., IL-1beta, IL-6, COX-2, and CCL-2) as effectively as dexamethasone (Dex). Dexamethasone 229-242 interleukin 1 alpha Homo sapiens 177-185 35110698-4 2022 HT-15 can selectively act on the NF-kappaB/AP1-mediated transrepression function of glucocorticoid receptor (GR) and repress the expression of pro-inflammation cytokines (i.e., IL-1beta, IL-6, COX-2, and CCL-2) as effectively as dexamethasone (Dex). Dexamethasone 244-247 interleukin 1 alpha Homo sapiens 177-185 2521831-4 1989 Dexamethasone (DXM) induced on RAJI cells a time-dependent increase in binding sites for both IL-1 beta and IL-1 alpha without affecting their binding affinities. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 108-118 2508093-4 1989 Treatment of the cells with human-recombinant interleukin 1 (IL-1), phorbol 12-myristate 13-acetate, or heparin-binding growth factor 1 enhanced the expression of APP gene in these cells, but calcium ionophore A23187 and dexamethasone did not. Dexamethasone 221-234 interleukin 1 alpha Homo sapiens 46-65 2521831-4 1989 Dexamethasone (DXM) induced on RAJI cells a time-dependent increase in binding sites for both IL-1 beta and IL-1 alpha without affecting their binding affinities. Dexamethasone 15-18 interleukin 1 alpha Homo sapiens 108-118 3136776-2 1988 It is now reported that MCCM, recombinant human IL-1 alpha (rHuIL-1 alpha), rHuIL-1 beta, and all-trans-retinoic acid elevate the u-PA messenger RNA (mRNA) levels to a steady-state value within 2 hours, while dexamethasone (10(-7)M) inhibits this increase. Dexamethasone 209-222 interleukin 1 alpha Homo sapiens 48-58 2646146-0 1989 Dexamethasone regulation of the expression of cytokine mRNAs induced by interleukin-1 in the astrocytoma cell line U373MG. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 72-85 2826581-2 1987 Release of IL-1 activity by bacterial toxin-stimulated cells was completely blocked by 10 nM dexamethasone (Dex). Dexamethasone 93-106 interleukin 1 alpha Homo sapiens 11-15 2470302-0 1988 Interleukin-1 alpha mRNA induced by cycloheximide PMA, and retinoic acid is reduced by dexamethasone in PAM-212 keratinocytes. Dexamethasone 87-100 interleukin 1 alpha Homo sapiens 0-19 2470302-3 1988 RU 486, which interferes with glucocorticosteroid-receptor binding, decreases inhibition of TPA stimulation of IL-1 alpha mRNA by dexamethasone, which suggests that the inhibition by dexamethasone is through a conventional ligand-receptor mechanism. Dexamethasone 130-143 interleukin 1 alpha Homo sapiens 111-121 2470302-3 1988 RU 486, which interferes with glucocorticosteroid-receptor binding, decreases inhibition of TPA stimulation of IL-1 alpha mRNA by dexamethasone, which suggests that the inhibition by dexamethasone is through a conventional ligand-receptor mechanism. Dexamethasone 183-196 interleukin 1 alpha Homo sapiens 111-121 2826581-2 1987 Release of IL-1 activity by bacterial toxin-stimulated cells was completely blocked by 10 nM dexamethasone (Dex). Dexamethasone 108-111 interleukin 1 alpha Homo sapiens 11-15 2826581-5 1987 Dex-mediated inhibition of IL-1 release appeared to be glucocorticoid receptor-mediated and was abrogated by progesterone. Dexamethasone 0-3 interleukin 1 alpha Homo sapiens 27-31 2826581-6 1987 In addition, Dex at high concentrations could inhibit post-transcriptional synthesis of IL-1 by prestimulated U937 cells. Dexamethasone 13-16 interleukin 1 alpha Homo sapiens 88-92 2826581-7 1987 Although Dex, 500 nM, did not change IL-1 mRNA levels in prestimulated cells, it completely blocked IL-1 release and induced a transient increase in cellular cyclic adenosine 3",5"-monophosphate (cAMP) levels. Dexamethasone 9-12 interleukin 1 alpha Homo sapiens 100-104 2824488-3 1987 We report that interleukin-1 induces the stromelysin gene, and dexamethasone diminishes the level of induction by interleukin-1, epidermal growth factor, phorbol ester, and cAMP elevation (elicited by cholera toxin). Dexamethasone 63-76 interleukin 1 alpha Homo sapiens 114-127 2826581-8 1987 Dex-mediated inhibition of IL-1 release in prestimulated cells is likely to occur via increased levels of cAMP, which have been shown to block post-transcriptional IL-1 synthesis. Dexamethasone 0-3 interleukin 1 alpha Homo sapiens 27-31 2826581-8 1987 Dex-mediated inhibition of IL-1 release in prestimulated cells is likely to occur via increased levels of cAMP, which have been shown to block post-transcriptional IL-1 synthesis. Dexamethasone 0-3 interleukin 1 alpha Homo sapiens 164-168 6600979-5 1983 The addition of macrophages (M phi) or interleukin 1 (IL1) was effective in removing the Dex inhibitory effect on T cells purified from PBL, but not on thymocytes. Dexamethasone 89-92 interleukin 1 alpha Homo sapiens 39-52 3498758-9 1987 Treatment of human lung fragments in vitro for 18 hr with glucocorticoids such as DEX and hydrocortisone resulted in dose dependent inhibition of IL-1 production; these and other glucocorticoids, at concentrations ranging between 0.1 and 1 microM, produced greater than 50% inhibition of IL-1 release. Dexamethasone 82-85 interleukin 1 alpha Homo sapiens 146-150 3498758-9 1987 Treatment of human lung fragments in vitro for 18 hr with glucocorticoids such as DEX and hydrocortisone resulted in dose dependent inhibition of IL-1 production; these and other glucocorticoids, at concentrations ranging between 0.1 and 1 microM, produced greater than 50% inhibition of IL-1 release. Dexamethasone 82-85 interleukin 1 alpha Homo sapiens 288-292 3498758-11 1987 Inhibition of IL-1 production occurred after a lag period 5 of 16 hr, and the relative glucocorticoid potencies agreed with their known anti-inflammatory potencies in vivo (beta-methasone approximately triamcinolone acetonide greater than DEX greater than fludrocortisone greater than prednisolone greater than hydrocortisone). Dexamethasone 239-242 interleukin 1 alpha Homo sapiens 14-18 3040777-0 1987 Dexamethasone inhibits feedback regulation of the mitogenic activity of tumor necrosis factor, interleukin-1, and epidermal growth factor in human fibroblasts. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 95-108 3040777-8 1987 Dexamethasone inhibited the increase of IFN-beta 2 mRNA levels by IL-1 or TNF. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 66-70 3040777-10 1987 Since IFNs suppress cell growth, inhibition of endogenous IFN-beta synthesis may also be responsible for the amplification by dexamethasone of the growth-stimulating action of TNF and IL-1. Dexamethasone 126-139 interleukin 1 alpha Homo sapiens 184-188 2429849-9 1986 In addition human interleukin-1 when tested in dexamethasone-treated test rats failed to induce neutrophil migration. Dexamethasone 47-60 interleukin 1 alpha Homo sapiens 18-31 3491698-4 1986 Monocytes preincubated in dexamethasone or hydrocortisone failed to exhibit any IL-1 activity in supernatants after LPS stimulation but the cell lysates still possessed 50% of control IL-1 activity. Dexamethasone 26-39 interleukin 1 alpha Homo sapiens 184-188 3500955-0 1987 Recombinant human interleukin-1 inhibits the induction by dexamethasone of alkaline phosphatase activity in murine capillary endothelial cells. Dexamethasone 58-71 interleukin 1 alpha Homo sapiens 18-31 3500955-3 1987 Dexamethasone increases the specific activity of alkaline phosphatase in a time- and dose-dependent fashion (maximum 14-fold induction at 10(-6) M, IC50 = 10(-8) M), and this induction can be completely inhibited by simultaneous incubation with picomolar concentrations of recombinant human IL-1 alpha or IL-1 beta. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 291-301 6603294-4 1983 In the presence of the macrophage product interleukin 1, the capacity of Dex to inhibit the mitogenesis of peripheral blood purified T cells (PBT) is inversely correlated with the PHA concentration used. Dexamethasone 73-76 interleukin 1 alpha Homo sapiens 42-55 6600979-5 1983 The addition of macrophages (M phi) or interleukin 1 (IL1) was effective in removing the Dex inhibitory effect on T cells purified from PBL, but not on thymocytes. Dexamethasone 89-92 interleukin 1 alpha Homo sapiens 54-57 6801116-4 1982 Interleukin 1, isolated from culture supernatants of PU5-1.8 and from culture supernatants of human acute monocytic leukemia cells, blocked the inhabitory effects of dexamethasone on colony formation in response to L929 CSF. Dexamethasone 166-179 interleukin 1 alpha Homo sapiens 0-13 6801116-5 1982 Moreover, dexamethasone inhibited colony formation in response to PU5-1.8 culture supernatants when interleukin 1 was absent. Dexamethasone 10-23 interleukin 1 alpha Homo sapiens 100-113 33672354-8 2021 Celecoxib and dexamethasone-loaded nanoparticles reduced the release of different inflammatory mediators (NO, TNF-alpha, IL-1beta, IL-6, PGE2 and IL-10) by lipopolysaccharide (LPS)-stimulated RAW264.7. Dexamethasone 14-27 interleukin 1 alpha Homo sapiens 121-129 33887367-6 2021 The signature apparently relates to TNF- alpha, IL-1alpha, IL-1beta, IFN-alpha, IFN-beta, and IFN-gamma signaling, but not IL-6 signaling, suggesting that therapeutic effect of dexamethasone in COVID-19 does not involve IL-6 pathway. Dexamethasone 177-190 interleukin 1 alpha Homo sapiens 48-57 33887367-6 2021 The signature apparently relates to TNF- alpha, IL-1alpha, IL-1beta, IFN-alpha, IFN-beta, and IFN-gamma signaling, but not IL-6 signaling, suggesting that therapeutic effect of dexamethasone in COVID-19 does not involve IL-6 pathway. Dexamethasone 177-190 interleukin 1 alpha Homo sapiens 59-67 33596205-14 2021 In sharp contrast, dexamethasone was able to control the capacity of pro-inflammatory cytokines, IL-1beta as well as TNFalpha, to stimulate mRNA levels of cPLA2alpha, COX-2 and mPGES-1. Dexamethasone 19-32 interleukin 1 alpha Homo sapiens 97-105 33023630-8 2020 RESULTS: DEX, but not IgG, significantly inhibited apoptosis caused by inflammatory stimuli, resulting in effective reduction of HMGB1 and IL-1alpha protein release by HCAECs. Dexamethasone 9-12 interleukin 1 alpha Homo sapiens 139-148 33023630-9 2020 As previously reported, DEX or IgG alone significantly suppressed TNF-alpha-induced production of IL-6 and G-CSF and mRNA expression, but induction of those cytokines by IL-1 s (IL-1alpha and IL-1beta) was resistant to high-dose IgG. Dexamethasone 24-27 interleukin 1 alpha Homo sapiens 178-187 33023630-9 2020 As previously reported, DEX or IgG alone significantly suppressed TNF-alpha-induced production of IL-6 and G-CSF and mRNA expression, but induction of those cytokines by IL-1 s (IL-1alpha and IL-1beta) was resistant to high-dose IgG. Dexamethasone 24-27 interleukin 1 alpha Homo sapiens 192-200 33413425-3 2021 Different concentrations of Dex were used to attenuate the inflammation induced by IL-1beta, and its effect was assessed via RT-PCR to detect inflammatory cytokine-related mRNA levels, including those of IKbeta-alpha, IKKbeta, IL-6, IL-8, and TNF-alpha. Dexamethasone 28-31 interleukin 1 alpha Homo sapiens 83-91 33073254-7 2020 As expected, DEX treatment suppressed multiple LPS-induced pro-inflammatory cytokines (IFN-gamma, IL-6, IL-8, IL-1beta, .TNF-alpha) by >85% and increased the anti-inflammatory cytokine IL-10 by 80%. Dexamethasone 13-16 interleukin 1 alpha Homo sapiens 110-118 32194233-5 2020 We demonstrated that dexamethasone in vitro given for 24 hours and followed by a 24-hour rest interval before an immune challenge potentiates inflammatory effects in these neural cells, that is, increases the IL-6 protein secretion induced by stimulation with IL-1beta (10ng/mL for 24 hours) by +49% (P<0.05) at a concentration of 100nM and by +70% (P<0.01) for 1muM. Dexamethasone 21-34 interleukin 1 alpha Homo sapiens 260-268 32412019-4 2020 The most effective PBAE identified enhanced DEX uptake by 8 folds compared to an equivalent dose of the commercial formulation and also prevented, through delivery of DEX, the cartilage degradation caused by IL-1alpha (interleukine1alpha). Dexamethasone 167-170 interleukin 1 alpha Homo sapiens 208-217 30026080-4 2018 We show that the presence of the dexamethasone prodrug LD003 effectively suppresses production of cytokines such as KC-GRO, TNFalpha, IL-1beta and IL-6 following intravenous administration of LNP loaded with immune stimulatory oligodeoxynucleotides containing cytosine-guanine dinucleotide motifs. Dexamethasone 33-46 interleukin 1 alpha Homo sapiens 134-142 31665239-4 2019 Here, we demonstrate that dexamethasone blocks interleukin-1 production in both bone marrow-derived and brain resident macrophage populations following stimulation with lipopolysaccharide and interferon gamma. Dexamethasone 26-39 interleukin 1 alpha Homo sapiens 47-60 31665239-5 2019 Additionally, dexamethasone is shown to inhibit downstream effectors of interleukin-1 signalling in both macrophage populations. Dexamethasone 14-27 interleukin 1 alpha Homo sapiens 72-85 31665239-10 2019 Collectively, this evidence suggests that interleukin-1 signalling inhibition and dexamethasone treatment share therapeutic efficacies and establishes interleukin-1 signalling as an attractive and specific therapeutic target for the management of glioblastoma-associated cerebral oedema. Dexamethasone 82-95 interleukin 1 alpha Homo sapiens 151-164 31221438-5 2019 RESULTS: Dexamethasone induced a semi-mature phenotype on TRIMEL/DC with low maturation surface marker expressions, decreased pro-inflammatory cytokine induction (IL-1beta and IL-12) and increased release of regulatory cytokines (IL-10 and TGF-beta). Dexamethasone 9-22 interleukin 1 alpha Homo sapiens 163-171 30805836-12 2019 Dexamethasone treatments resulted in the most profound dysregulation of expression of NO, TNF, IL-1beta, NGF, CD68, and MHCII as well as ramified morphology and uptake of myelin. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 95-103 28078769-8 2017 IL-1alpha induced IL-8 in bronchial epithelial cells, which was dose-dependently inhibited by dexamethasone but not by azithromycin. Dexamethasone 94-107 interleukin 1 alpha Homo sapiens 0-9 22300324-7 2012 KEY RESULTS: TGF-beta (40-400 pM) reduced the maximum inhibitory effect of dexamethasone on IL-1alpha-induced IL-6 and CXCL8 production. Dexamethasone 75-88 interleukin 1 alpha Homo sapiens 92-101 20845101-11 2010 Dexamethasone significantly reduced postoperative levels of CRP (p = 0.01), IL-6 and IL-1 (p < 0.05), fatigue (p = 0.01) and overall pain during the first 24 postoperative hours (p < 0.05) and the total requirement of analgesic (ketorolac) (p < 0.05). Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 85-89 27417275-13 2017 CONCLUSIONS: Intravitreal dexamethasone treatment resulted in alterations in the concentrations of pro-inflammatory cytokines MCP-1 and IL17-E in patients with BRVO and MCP-1 and IL1-alpha in patients with CRVO. Dexamethasone 26-39 interleukin 1 alpha Homo sapiens 179-188 26956216-0 2016 Dexamethasone Release from Within Engineered Cartilage as a Chondroprotective Strategy Against Interleukin-1alpha. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 95-113 26956216-3 2016 This study tested the hypothesis that the incorporation of poly(lactic-co-glycolic acid) (PLGA) (75:25) microspheres that release dexamethasone from within chondrocyte-seeded agarose hydrogel constructs would promote development of constructs with functional properties and protect constructs from the deleterious effects of interleukin-1alpha (IL-1alpha). Dexamethasone 130-143 interleukin 1 alpha Homo sapiens 325-343 26956216-3 2016 This study tested the hypothesis that the incorporation of poly(lactic-co-glycolic acid) (PLGA) (75:25) microspheres that release dexamethasone from within chondrocyte-seeded agarose hydrogel constructs would promote development of constructs with functional properties and protect constructs from the deleterious effects of interleukin-1alpha (IL-1alpha). Dexamethasone 130-143 interleukin 1 alpha Homo sapiens 345-354 20346081-9 2010 Dexamethasone, at 50 microg/ml, decreased the viability of HRECs stimulated by IL-1alpha, IL-1beta, IL-6 and VEGF without hyalocytes but could not decrease the viability of HRECs cocultured. Dexamethasone 0-13 interleukin 1 alpha Homo sapiens 79-88 19156359-8 2009 This increase could also be induced by macrophage-conditioned medium, tumor necrosis factor-alpha, IL-1alpha, and IL-1beta, and could be suppressed by anti-inflammatory agents including pyrrolidine dithiocarbamate, pentoxifylline, or dexamethasone. Dexamethasone 234-247 interleukin 1 alpha Homo sapiens 99-108